AbbVie Announces Publication Of Results Of Phase 4 IMMpulse Study Of SKYRIZI, Which Achieved All Primary And Ranked Secondary Endpoints
Portfolio Pulse from Bill Haddad
AbbVie has announced the publication of results from its Phase 4 IMMpulse study of SKYRIZI, which achieved all primary and ranked secondary endpoints. This suggests a positive development in the company's drug pipeline.
July 26, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's successful Phase 4 IMMpulse study of SKYRIZI is a positive development for the company's drug pipeline, which could potentially boost its stock in the short term.
The successful completion of a Phase 4 study is a significant milestone in a drug's development and can lead to increased investor confidence in the company's ability to bring new products to market. This could potentially lead to an increase in AbbVie's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100